{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:08Z","timestamp":1789746188689,"version":"4.0.1"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,15]]},"DOI":"10.2169\/internalmedicine.4550-20","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T22:11:32Z","timestamp":1590185492000},"page":"2003-2008","source":"Crossref","is-referenced-by-count":15,"title":["Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment"],"prefix":"10.2169","volume":"59","author":[{"given":"Yumiko","family":"Samejima","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Iuchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nasu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ezumi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunimitsu","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hirashima","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895, 1992.","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"2","unstructured":"2. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.","DOI":"10.1056\/NEJMoa1200690"},{"key":"4","unstructured":"4. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14: 1212-1218, 2013."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015.","DOI":"10.1056\/NEJMoa1504627"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"7. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387: 1540-1550, 2016.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"8","unstructured":"8. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.","DOI":"10.1056\/NEJMoa1606774"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078-2092, 2018.","DOI":"10.1056\/NEJMoa1801005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379: 2040-2051, 2018.","DOI":"10.1056\/NEJMoa1810865"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378: 2288-2301, 2018.","DOI":"10.1056\/NEJMoa1716948"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379: 2220-2229, 2018.","DOI":"10.1056\/NEJMoa1809064"},{"key":"14","unstructured":"14. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"15","doi-asserted-by":"crossref","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"15. Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2: e000247, 2017.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375: 1749-1755, 2016.","DOI":"10.1056\/NEJMoa1609214"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136: 2085-2087, 2017.","DOI":"10.1161\/CIRCULATIONAHA.117.030571"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19: e447-e458, 2018.","DOI":"10.1016\/S1470-2045(18)30457-1"},{"key":"19","unstructured":"19. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3: 4, 2015."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4: 50, 2016.","DOI":"10.1186\/s40425-016-0152-y"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Anderson RD, Brooks M. Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy. Int J Cardiol 222: 760-761, 2016.","DOI":"10.1016\/j.ijcard.2016.07.291"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ederhy S, Cautela J, Ancedy Y, Escudier M, Thuny F, Cohen A. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 11: 1187-1190, 2018.","DOI":"10.1016\/j.jcmg.2017.11.036"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319-322, 2001.","DOI":"10.1126\/science.291.5502.319"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9: 1477-1483, 2003.","DOI":"10.1038\/nm955"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 101: 248-257, 2007.","DOI":"10.1161\/CIRCRESAHA.106.147124"},{"key":"26","unstructured":"26. Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153. PLoS One 10: e0124059, 2015."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71: 1755-1764, 2018.","DOI":"10.1016\/S0735-1097(18)31240-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4550-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:28:47Z","timestamp":1666632527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4550-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4550-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}